HIGHLIGHTS
- who: Tejminder S. Sidhu et al. from the Australian Centre for Blood Diseases and Department of Clinical Haematology, Monash University have published the Article: Differential Signaling by Protease-Activated Receptors: Implications for Therapeutic Targeting, in the Journal: (JOURNAL)
- what: Whereas much of the research on platelet PARs has focused on PAR1, PAR4 has largely been ignored. Given their potential impact on current and future therapeutic approaches, the authors focus on these particular PAR heterodimers below. This work shows one potential advantage of inhibiting PAR1-PAR4 heterodimerization versus the more standard receptor antagonist approaches utilized by . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.